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ttp://dx.doi.org/10.1016/j.ajpath.2013.06.012Despite important progress in adjuvant and neoadjuvant therapies, metastatic disease often develops in
breast cancer patients and remains the leading cause of their deaths. For patientswith establishedmetastatic
disease, therapy is palliative, with few breaks and with mounting adverse effects. Many have hypothesized
that a personalized or precision approach (the terms are used interchangeably) to cancer therapy, in which
treatment is based on the individual characteristics of each patient, will provide better outcomes. Here, we
discuss the molecular basis of breast cancer metastasis and the challenges in personalization of treatment.
The instability of metastatic tumors remains a leading obstacle to personalization, because information from
a patient’s primary tumor may not accurately reﬂect the metastasis, and one metastasis may vary from
another. Furthermore, the variable presence of tumor subpopulations, such as stem cells and dormant cells,
may increase the complexity of the targeted treatments needed. Although molecular signatures and circu-
lating biomarkers have been identiﬁed inbreast cancer, there is lackof validatedpredictivemolecularmarkers
to optimize treatment choices for either prevention or treatment of metastatic disease. Finally, to maximize
the information that can be obtained, increased attention to clinical trial design in themetastasis preventive
setting is needed. (Am J Pathol 2013, 183: 1084e1095; http://dx.doi.org/10.1016/j.ajpath.2013.06.012)Supported by the Intramural Program of the National Cancer Institute.
This article is dedicated to the memory of Maria Wetzel, who died of
breast cancer in May 2013.
Current address of J.N., Department of Biological Sciences, National
University of Singapore, Singapore.
This article is part of a review series on the molecular pathogenesis of
breast cancer.Although personalizing the treatment of breast and other
cancers is a promising goal, individualizing treatments will
require a wealth of newmolecular data and therapeutic options.
Much of the recent progress has been in personalizing treatment
of early breast cancer. These efforts havemovedbeyondalready
established therapies for patients with estrogen receptore
positive (ERþ) and/or progesterone receptorepositive (PRþ)
and HER2-overexpressing (HER2þ) disease, primarily using
multigene assays that are prognostic for risk of recurrence and
predictive for response to cytotoxic chemotherapy.stigative Pathology.
.Personalized medicine for metastatic disease presents
greater hurdles, however. The complexity, heterogeneity, and
genomic instability of metastatic breast cancer cells make
Table 1 Hallmarks of Metastasis and Their Implications for Personalized Medicine
Hallmark Implications for Personalized Medicine
Heterogeneity between primary tumors and metastases,
and among metastases
Therapy based on primary tumor characteristics may not be effective
Redundancy of mechanistic pathways Need for combination therapies
Variable dormancy Clinical trials must address delayed relapses
Contributions of cancer-initiating cells Incorporation of therapies that target stem cells
Challenges in Breast Cancer Metastasistheir evaluation and therapy a challenging process (Table 1).
Thus, although this review sheds light on potentially impor-
tant aspects of personalized medicine in metastatic breast
cancer, the potential remains to be realized.
Metastasis has been described mechanistically as the
migration of tumor cells from the primary tumor, followed by
intravasation, survival, extravasation of the circulatory
system, and progressive colonization of a distant site.1e3 This
mechanistic description does not capture other equally valid
characteristics, however. In a second deﬁnition, that of
parallel progression, the deﬁning feature is tumor cell
genomic instability, promoting selection for characteristics
that enable invasion and distant organ colonization.4 From
this perspective, it is not the steps in metastasis that are
critical, but rather the instability that fuels the process. In yet
another deﬁnition, metastasis is described in terms of seed
and soil.5 Tumor cells (seeds) spread widely through the
body, but grow only in supportive locations (congenial soil).
Thus the various microenvironments (soils) of metastases
contribute to the observed heterogeneity. Layered over the
fundamentals of the metastatic process is acquired or innate
resistance to therapies. Because only 5% of breast cancer
patients have stage IV disease at initial diagnosis (http://
www.seer.cancer.gov/statfacts/html/breast.html; accessed
February 1, 2013), in the majority of metastatic patients the
metastatic disease develops after hormone therapy, chemo-
therapy, or biologics have been used in adjuvant treatment.
Another hallmark of metastasis is the redundancy of
pathways that mediate the process or its component steps.
Genes promoting breast cancer metastasis abound,
including ERBB2 (alias HER2, NEU), CTNNB1, KRAS,
PI3KCA (alias PI3K), EGFR, MYC, TWIST1, SNAI1 (alias
SNAIL), SNAI2, MET, and ID1.6 Some genes are involved
in tumor cell survival and colonization in the metastatic
site in a generalized manner, including PTGS2, EREG,
MMP1, LOX, ANGPTL4, and CCL5. Other genes, such as
PTHLH (alias PTHRP), IL11, CSF2RB, IL6, and TNF
(previously TNFA) function in a more organ-speciﬁc
manner.6 Several of these pathways in genetically engi-
neered mouse models exhibit oncogene addiction, with the
ablation of the expression of a single gene causing tumor
regression.7 Does this portend better responses to pathway
inhibitors? Most pathways are only partial contributors to
the metastatic process, meaning that their inhibition would
have at-best partial effects and could be overcome by other
contributory pathways. Additional pathways suppress
metastasis, either by inhibiting tumorigenesis8 or byThe American Journal of Pathology - ajp.amjpathol.orgspeciﬁcally suppressing the metastatic process, the latter
deﬁned as metastasis suppressor genes.9,10 Successful
personalized medicine approaches will have to deal with
the instability, complexity, and multifactorial nature of the
metastatic process.
Research into the metastatic process is relevant to
personalizing both the adjuvant and metastatic clinical
settings. In the adjuvant setting, micrometastases are
thought to be present, and systemic therapy is adminis-
tered to prevent their outgrowth. In the metastatic setting,
treatment aims to shrink lesions that have completed the
metastatic process and to prevent the outgrowth of further
metastases. Both preclinical and clinical data suggest that
a given drug may not be equally effective in both settings.Factors Important to Personalizing Therapy for
Preventing and Treating Metastatic Disease
Semipersonalized Medicine
There appear to be degrees of personalized medicine. Semi-
personalized medicine is based on the identiﬁcation of large
groups of patients with certain tumor characteristics that can
direct a given patient to corresponding speciﬁc types of
therapy. True personalized medicine would be based on an
individual patient’s tumor, directing to a tailored therapy
maximized for effectiveness for that one patient in particular.
Semipersonalized medicine has already generated effective
therapies for groups of patients and thus can provide a basis for
personalized approaches. Here, we address three examples:
HER2-directed therapies, anti-estrogenic therapies, and
bisphosphonate and antibody therapies.
HER2-Directed Therapies
The tyrosine kinase receptor proto-oncogene c-ErbB-2
(hereafter referred to by the familiar alias HER2) is overex-
pressed or ampliﬁed in approximately 25% of breast cancers,
and is a signiﬁcant prognostic marker of shorter relapse-free
and overall survival.11 HER2 is a transmembrane tyrosine
kinase receptor and a member of the EGFR family, which
also includes HER1 (EGFR), HER3, and HER4. Addition-
ally, HER2 can interact reversibly with ligand-activated
family members to form active heterodimers, leading to
phosphorylation of intracellular tyrosine residues. This acti-
vation recruits cytoplasmatic signal transducers such as
STAT, p85-PI3K, PLC-g, and Src. Two of the main1085
Marino et aldownstream pathways activated by HER2 are the MAPK and
PI3KeAKT pathways promoting cell survival, cell prolif-
eration, and migration.12
HER2þ breast cancer patients derive signiﬁcant beneﬁt
from HER2-targeted therapy, such as the humanized
monoclonal antibody trastuzumab combined with chemo-
therapy in the adjuvant and metastatic settings.13 Although
the beneﬁt of trastuzumab-based therapy is undeniable,
approximately 50% of HER2-overexpressing breast cancers
do not respond to trastuzumab,13 suggesting the need for
greater precision. Lapatinib, a small-molecule inhibitor of
HER2 and EGFR, has shown efﬁcacy in the metastatic
setting after relapse on trastuzumab-based therapy.14 Several
newer therapies aimed at the HER superfamily (EGFR and
HER2 to HER4) have been approved or are in late devel-
opment; these include pertuzumab15 and trastuzumab
emtansine (T-DM1).16 These vary in potency and speciﬁc
target within the superfamily.
In animal models, overexpression of HER2 promotes
metastasis to lymphnode, lung, bone, andbrain.17e19Studiesof
HER2 promotion of metastasis have identiﬁed several path-
ways, including a bidirectional interaction with the TGF-b/
Smad pathway,20 an increase in expression and stability of the
homing chemokine receptor CXCR4,21 an activation of Src
with consequent phosphorylation of FAKtyr861 and activation
of p120/Rac1/Cdc42,22 and an increase in angiogenesis
through up-regulation of VEGF23 and angiopoietin-2.24 It will
be of interest to determinewhether inhibitors of these pathways,
in combination with HER2 therapy, provide a better degree of
metastasis prevention or shrinkage of established lesions.
Anti-Estrogenic Therapies
At diagnosis, 75% of breast tumors are ERþ and can poten-
tially respond to tamoxifen, aromatase inhibitors, or other
hormonal therapies.25,26 ERþ tumors tend to metastasize to
the bone,27 and often metastasize late.28 A recent long-term
follow-up study after 5 years of tamoxifen therapy showed
that metastatic relapses continue over the next 10 years and
have not leveled off at that time point, suggesting a contin-
uous break from dormancy.29
Estrogen effects are mediated by two speciﬁc nuclear
receptors, estrogen receptor a (ER-a) and estrogen receptor
b (ER-b). ER-a is expressed in breast and is associated with
increased proliferation and metastasis. On binding to the
ligand, ER regulates the transcription of target genes. ER
can also form multiprotein complexes with membrane-
related factors such as Src, G-proteins, RTK, and PELP1.30
Downstream of ER lies the activation of Src, Ras, and
MAPK signaling to promote cell proliferation, PI3KeAkt
to induce survival and invasion, and the Rho family
GTPases Rac and Cdc42 to promote cell migration, inva-
sion of the extracellular matrix, and metastasis.31 Crosstalk
between ER signaling and growth factor pathways is
correlated with both cancer progression and resistance to
hormonal therapy.32 A link between ER signaling and the
epithelialemesenchymal transition has been described.331086Finally, estrogen affects the cytokine milieu in the cancer
microenvironment.34
The wide range of endocrine therapy options provides an
opportunity to select the optimal sequence and combination
of therapeutic agents after recurrence or relapse. Current
strategies focus on combinations with growth factor and PI3
kinase pathway targeting agents, such as geﬁtinib and ever-
olimus.35,36 Combinations with other pathway inhibitors may
hold promise. The potential of gene signatures for individu-
alizing therapy in the ERþ setting is under testing in the
TAILORx trial. The purpose of this randomized phase III
trial is to identify the best individual therapy for node-
negative, ERþ breast cancer patients, classifying them by
using the 21-gene signature Oncotype DX.37 If validated, this
signature could provide patients with an individualized esti-
mate of therapeutic beneﬁt.
Bisphosphonates and RANKL Antibody
Breast cancer patients with bone metastases have distinct
therapeutic options, including bisphosphonates and (more
recently) denosumab, typically in combination with endo-
crine or HER2-directed therapies. The bone metastatic
process has been described as a vicious cycle.38 Alterations
in the bone microenvironment are the initiators of this cycle;
major changes include hypoxia, acidic pH, and increased
levels of extracellular calcium and growth factors.39 The
osteolytic vicious cycle is characterized as bone lysis with
concurrent inﬁltration of metastatic tumor cells. TGF-b and
parathyroid hormone-related protein (PTHrP) both play an
important role in osteolysis. PTHrP, produced by tumor
cells, activates osteoblasts and osteoclasts via the RANK
ligand (RANKL) pathway, resulting in bone resorption.
Bone resorption releases growth factors, ionized calcium,
and ionized phosphate. Release of ionized calcium results in
an elevation of circulating PTHrP, increasing the propensity
for osteolysis by osteoclasts and thus promoting the vicious
cycle. Release of growth factors from the bone matrix, such
as TGF-b, in turn activates tumor cells, contributing to the
cycle.39 Denosumab is a human monoclonal antibody
against RANKL. In a phase III trial, denosumab reduced the
risk of developing multiple skeletal-related events (time to
ﬁrst and subsequent events) by 23%, compared with the
bisphosphonate zoledronic acid.40
It must be noted that one consequence of semi-
personalized medicine is that some patients will be over-
treated, because not all members of the large groups on
which semipersonalized treatment is based will beneﬁt alike.
Factors That We Ignore at Our Peril
Metastatic disease is largely incurable because of the very
factors that deﬁne it (Figure 1). As precision treatment
approaches develop in the adjuvant and metastatic settings,
consideration must be given in trial design to these factors:
heterogeneity, genomic instability, sites of metastasis, tumor
subpopulations, and microenvironmental inﬂuences.ajp.amjpathol.org - The American Journal of Pathology
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Figure 1 The complex of challenges in person-
alizing therapy in breast cancer metastasis. Metas-
tasis is an intricate disease state, and many aspects
of its biology and origin remain poorly understood.
Thus, the complexity of the disease (with its genetic
instability, tumor heterogeneity, and dormancy
phenotype) limits accurate diagnosis and tailoring
of treatments for patients. The lack of validated
predictive biomarkers able to determine treatment
choice and scarcity of metastasis-speciﬁc clinical
trials constitutes a further limitation for imple-
mentation of personalizedmedicine in breast cancer
metastasis.
Challenges in Breast Cancer MetastasisHeterogeneity
Recent research has demonstrated heterogeneity in primary
tumors and corresponding breast cancer metastases at the
morphological, molecular, and genomic levels, and such
heterogeneity may be a signiﬁcant determinant of anticancer
therapy response.41 Studies evaluating the traditional
markers HER2, ER, and PR indicate 5% to 22%, 13% to
33%, and 31% to 32% discordance, respectively, between
primary tumor and distant metastases.42e44 A retrospective
study of 255 patients with matched primary breast cancer
and liver metastatic samples available for evaluation re-
ported discordance of 14.5%, 48.6%, and 13.9% for ER,
PR, and HER2, respectively.45 Interestingly, the authors
reported the inﬂuence of receptor status discordance on the
therapeutic regimen: based on the metastatic biopsy, treat-
ment was changed for 12.1% of the patients. Larger studies
will be needed to fully assess the frequency and potential
beneﬁts of altering therapy because of discordance of tumor
characteristics in metastatic sites.
For other therapeutic targets, discordance between primary
tumors and metastases reigns. Akcakanat et al46 determined
whether primary tumors differed from their metastases in
their expression of p-Akt and p-4E-BP1, components of the
therapeutically relevant PI3K pathway. They observed poor
concordance between immunohistochemical levels of p-Akt
and p-4E-BP1 expression in primary tumors and metastases.
Wu et al47 observed extensive heterogeneity between
primary breast carcinomas and their paired metastases, as
well as amongmultiple metastatic breast carcinomas from the
same patient. They observed down-regulation of ER and PR
and overexpression of COX-2, MET, EGFR, and mesothelin
in metastatic versus primary lesions, and they concluded that
therapeutic targets identiﬁed in the primary breast carcinoma,
or even in some metastatic breast carcinomas, might not
reﬂect targets present in all metastatic sites.47 DNA methyl-
ation of ﬁve marker genes [CCND2, RARB, TWIST1,
SCGB3A1 (alias HIN1), and RASSF1] has been reported toThe American Journal of Pathology - ajp.amjpathol.orgbe discordant between primary tumor and metastasis, and
between metastases in a warm autopsy study.48
Mutational proﬁling of breast cancer metastases and either
matched or unmatched primary tumors has recently identiﬁed
a number of genetic alterations that, although not unique to
metastases, occur more frequently in secondary lesions. For
example, mutations in the tumor-suppressor gene TP53,
which occur in roughly a quarter of primary breast carci-
nomas, were found at higher frequency (87%) in a series of 23
brain metastases of breast cancer, with a striking preponder-
ance of complex TP53 mutations, such as frameshift, splice,
and nonsense mutations, as well as in-frame insertions and
deletions.49 Increased ampliﬁcation of MYC in systemic
metastases compared with primary breast tumors has been
described.50 In brain metastases, the tumor-suppressor PTEN
was more frequently mutated or lost because of allelic
imbalance, compared with primary breast tumors.51
Recently, advanced next-generation sequencing tech-
niques have been used to interrogatewhole cancer genomes at
the single-nucleotide level and have distinguished between
mutations in breast cancer metastases that are present in rare
cell populations of the primary tumor and to those arising de
novo during metastatic progression. In the brain-metastatic
progression of a basal-like breast cancer, most mutations
were shared between the primary tumor and the metastasis,
although a signiﬁcant enrichment of missense mutations in
NRK (a JNK activating protein kinase), PTPRJ (a protein
tyrosine phosphatase), and WWRTR1 (a modulator of
mesenchymal stem cell differentiation) was observed in the
metastatic lesion.52 In contrast, the majority of mutations
present in a metastatic lobular breast cancer specimen were
not present in the primary tumor, suggesting substantial
genetic evolution during the metastatic process.53
These data highlight two concerning ﬁndings. First, we
cannot accurately predict the molecular proﬁle of metastatic
disease by proﬁling the primary tumor. Second, one
metastasis may be distinct from another within the same1087
Marino et alindividual. Effective personalized medicine will have to
account not only for a person’s individual primary tumor
data, but also for variances within and between metastases.
Moreover, we still lack drugs targeting many of the newly
identiﬁed pathways that are altered in metastatic lesions.
The creation of new therapies based on detailed molecular
proﬁling remains challenging.
Genomic Instability
The instability of metastatic breast cancer cells likely drives
heterogeneity. Comparative genomic hybridization has been
used as a tool to identify large scale genomic instability and
identiﬁed two classes of breast cancer genomic structure:
monogenomic, with one major clonal subpopulation with
high chromosomal stability, and polygenomic, with multiple
clonal subpopulations. Polygenomic clones may have
shared or segregated anatomical distributions. Disparate
clonal evolution may explain molecular discordance at the
time of disease relapse.54 Comparison of the primary tumor
and concurrent lymph node inﬁltrates using comparative
genomic hybridization revealed extensive clonal genomic
heterogeneity, indicating that the evolution of tumors can
begin early.55 In addition, adjuvant therapy may contribute
to biological discordance by clonal selection pressure,
exempliﬁed by the evolution of ER subpopulations after
endocrine therapy for predominantly ERþ disease.
Failure in the DNA break repair system, mitotic chro-
mosome transmission, or the spindle mitotic checkpoint can
cause the chromosomal lesions that are hallmarks of
genomic instability. Consequently, high mutation rates and
chromosomal rearrangements (deletions, duplications, and
ampliﬁcations) may drive tumor progression by disruption
of tumor-suppressor genes, formation of fusion proteins,
constitutive activation of enzymes, or ampliﬁcation of
oncogenes.56 Whole-genome sequencing analyses of breast
cancers revealed unexpectedly high levels of somatic
mutations,57 which may confer a selective advantage on the
tumor cells and thus promote their clonal expansion.
Sites of Metastasis
The extent to which metastases are site speciﬁc remains
poorly understood. Certainly the vicious cycle has been
established as being important to bone metastasis.39 How-
ever, other pathways also contribute to bone metastasis, and
PTHrP, involved in the vicious cycle for bone, has been
implicated in metastasis to other sites.58 Speciﬁc therapies are
available for patients with bone metastases, and these need to
be factored in for a personalized regimen. Other pathways
have been reported to mediate lung59 and liver metastasis.60
Our research group and others have investigated brain-
permeable compounds that prevent the formation of brain
metastases or could potentially prevent the development of
additional brain metastases in patients with a limited number
of lesions. Lapatinib is the only traditional breast cancer drug,
of 18 drugs tested, that has brain metastasis preventive
activity in the HER2þ setting.61,62 In the model used,1088however, HER3 activation was lacking in the tumor cells;
other models with activated HER3 signaling may show more
resistance. Personalization of these trends would require the
identiﬁcation of those patients with HER2þ tumors at highest
risk for development of brain metastases, as well as an
understanding of the complex signaling pathways involved.
A prospective study showed that 37.3% of all metastatic
breast cancer patients with HER2þ tumors developed brain
metastases over 7.1 to 13.3months of follow-up,63 but further
personalization of this trend is needed. Several attempts have
been reported in preliminary form, but none have been
prospectively conﬁrmed.64 Other drugs that can partially
prevent the formation of brain metastases in preclinical
models but are not part of the breast cancer armamentarium
include pazopanib,65 a Plk1 inhibitor,66 vorinostat,67 and
TPI-287.68 Guidance is needed to identify which patients
would beneﬁt from these nontraditional therapies.
Tumor Subpopulations
In addition to molecular heterogeneity, subpopulations of
tumor cells with distinct functional capabilities may exist,
and these would need to be factored in for any successful
personalized treatment.
Tumor stem cells or cancer-initiating cells may be one
subpopulation. Stem cells are deﬁned as cells that have the
ability to perpetuate themselves through self-renewal and to
generate mature cells of a particular tissue through differenti-
ation.69 A small subpopulation of tumor cells characterized
by CD44þCD24/low was enriched in stem cell-like proper-
ties.70 In addition to the CD44þCD24/low subpopulation,
aldehyde dehydrogenase 1 [encoded byALDH1A1 (previously
ALDH1)] was reported to identify stem cell-like properties on
breast cancer cells. Both aldehyde dehydrogenase and CD44/
CD24 expression have been linked to aggressive metastatic
behavior.71Metastasis is an inefﬁcient process, and very few of
the cells released from a primary tumor can reinitiate tumor
growth at distant sites.72 The formation of metastases has been
thought to result from the dissemination of cancer cells pos-
sessing stem cell-like properties and their proliferation at
distant sites. Stem cell-like properties have been proposed to
confer not only metastatic potential but also chemotherapy
resistance.73 Recently, a plasticity model was proposed by
Polyak, Weinberg, and colleagues.74 They demonstrated in
mammalian breast cells that undifferentiated CD44/low-
CD24
þ
epithelial cells can revert to a stem-like state
(CD44þCD24/low), driven by the epithelialemesenchymal
transition. To our knowledge, it remains uncertain whether
tumor stem cells also evolve in the metastatic process, which
would determine whether the stem cell subpopulation from the
primary tumor resection is adequate.
Another tumor subpopulation that we ignore at our peril
is dormant tumor cells. For some breast cancer patients,
metastasis occurs soon after a primary tumor develops,
whereas for other patients metastases emerge years or even
decades after initial treatment. Tumor cells that remain
latent for a prolonged period of time are termed dormant.ajp.amjpathol.org - The American Journal of Pathology
Challenges in Breast Cancer MetastasisDormancy itself can be heterogeneous, reﬂecting a balance
of proliferation and apoptosis, cell cycle quiescence, and/or
antiangiogenic mechanisms.75,76 An experimental study
demonstrated doxorubicin resistance in dormant breast
cancer cells,77 which suggests that these cells can survive
initial chemotherapy and awaken later.
To address the chemoresistance of dormant tumor cells,
novel therapeutic strategies based on mechanistic pathways
mediating dormancy are needed. Several clues have
emerged from the preclinical literature. When HEp3 cells
were xenografted into the immunodeﬁcient chick embryo,
dormancy was accompanied by a balance between reduced
activation of ERK proliferative MAP kinase and elevated
activation of p38 stress MAP kinase; this balance was
regulated by the urokinase receptor and by interactions with
ﬁbronectin.78 A similar inverse balance between ERK and
p38 was observed in other models.79 The data suggest that
p38-activating drugs or ERK inhibitors hold beneﬁt. The
lysophosphatidic acid receptor 1 (LPA-1) inhibitor Debio
0719 signiﬁcantly decreased metastatic progression in two
triple-negative breast cancer model systems using the
murine mammary carcinoma cell line 4T1 and human breast
cancer cell line MDA-MB-231. The inhibitor prevented
these cells from proliferating in distant organs such as liver
and lung, as evidenced by reduced Ki-67 staining; cancer
cells in distant organs in the inhibitor-treated mice showed
a reduction in ERK activation and an increase in p38 acti-
vation.79 In a three-dimensional culture system, inhibition of
integrin b1 or MLCK prevented transition from a quiescent
to a proliferative state,80 which has been reported also in
other models.81 These studies suggest that integrin b1
inhibitors may control dormancy.
Regardless of personalized medicine approaches, clinical
trial designs to validate dormancy-maintenance regimens
will need new designs and endpoints. We currently have no
validated mechanism to determine whether a patient harbors
dormant tumor cells, nor for evaluating the potential of any
such cells for awakening or their molecular characteristics.
Disseminated tumor cells in the bone marrow have been
proposed as a potential reservoir for dormant tumor cells to
nest, and their presence is prognostic.82 However, we do not
know what proportion of tumor cells reside in bone marrow
versus in the secondary organs, and the invasiveness of bone
marrow biopsies precludes their routine use.
Microenvironmental Inﬂuences
A major contributor to tumor metastasis is the tumor
microenvironment, which includes ﬁbroblasts, vasculature,
immune and inﬂammatory cells, and extracellular matrix.
Microenvironments (also known as niches) participate in
reciprocal interactions between tumor cells and their
surroundings.83 Microenvironments are not static. They are
modiﬁed by tumor cells and inﬁltrated by immune and
other circulating cells, a state often referred to as reactive; in
turn, the reactive microenvironment can fuel tumor
progression. To date, a complete portrait of the metastaticThe American Journal of Pathology - ajp.amjpathol.orgmicroenvironment by organ site, through time, is lacking
even in experimental models. Layered onto this lack of basic
information is limited understanding of the role that the
microenvironment plays in chemotherapeutic resistance.83
Simplistically, aspects of the microenvironment have
been targeted for interruption (eg, angiogenesis). Again
simplistically, this complex process has been reduced to the
angiogenesis promoter VEGF (targeted by bevacizumab) or
a handful of angiogenesis receptors such as VEGFRs and
PDGFRs (targeted by sorafenib, pazopanib, and other
kinase inhibitors). Although the U.S. Food and Drug
Administration (FDA) has approved bevacizumab for
certain metastatic cancer indications, conditional approval
in metastatic breast cancer was withdrawn over efﬁcacy
and toxicity concerns (http://www.cancer.gov/cancertopics/
druginfo/fda-bevacizumab, last accessed February 1, 2013).
In terms of efﬁcacy, there is much that we do not understand.
For example, the reliance of metastasis on angiogenesis (as
opposed to co-option of the existing vasculature or other
mechanisms) is debated,84 an effect of angiogenesis on
hypoxia-induced tumor progression has been reported,85 and
other angiogenic factors and receptors are known to exist.84
Such detailed knowledge of microenvironmental evolution
will be critical to identifying newer and more effective
metastasis preventive and therapeutic strategies and to their
eventual personalization.
Oligometastatic or Limited Metastatic Disease?
The clinical state of oligometastatic disease, as described in
1995 byHellman andWeichselbaum,86 refers to a subgroup of
cancer patients with a limited metastatic burden. In general,
only one organ is involved, and with only a single detectable
metastatic lesion. Does the oligometastatic state beneﬁt from
distinct treatments, and would its personalization be different?
Given their relatively limited nature, oligometastases could be
removed by local therapy, such as surgical excision or
stereotactic radiotherapy. In some cases, local therapy is fol-
lowed by a systemic treatment similar to adjuvant therapy, to
reduce possible subclinical systemic spreading of the meta-
static disease. For a subgroup of oligometastatic breast cancer
patients, the multidisciplinary approach may be curative. The
selection of a subgroup of oligometastatic patients that may
beneﬁt from aggressive local treatment, currently based on
a long disease-free interval, young age, good performance
status, negative HER2 status, and a low number of involved
sites,87 can be reﬁned to more personalized levels.
Approaches to Personalized Medicine for
Metastatic Breast Cancer
Can Prognostic and Predictive Signatures Guide
Individualized Therapy?
In addition to standard histopathological tools, a number of
multigene expression signatures have been identiﬁed for1089
Marino et alestimating the natural history of the disease. Although there
is generally little overlap among the genes in these signa-
tures, most prognostic signatures are related to tumor
proliferation phenotypes. The two most commonly consid-
ered platforms, MammaPrint (Agendia, Amsterdam,
Netherlands; Irvine, CA) and Oncotype DX (Genomic
Health, Redwood City, CA), for example, have only one
gene in common.88,89 Immunohistochemical detection of
Ki-67 is a relatively inexpensive, well-established prolifer-
ation marker in breast cancer with demonstrated predictive
power.90 The predictive ability of these platforms may be
useful for personalization of therapy to prevent metastasis.
Another relevant question is whether signatures based
on characteristics other than proliferation (eg, dormancy,
stemness, or metastatic colonization potential) may hold
greater potential for personalizing the prevention of metas-
tasis. A starting point would be to determine what tumor
cohorts with what follow-up data are needed, to be collected
as a centralized resource for validation of potential signatures.
Metastatic Biopsies
As noted above, a substantial number of patients have
discordant ﬁndings between matched biopsies of primary
tumor and metastatic sites. Furthermore, one metastasis may
differ from another within the same individual, raising the
question of how many biopsies are needed. Biopsy of meta-
static tissue could potentially improve outcome by identifying
what new genetic or molecular pathways are activated, leading
to altered and ideally more efﬁcacious therapy. In 2011, the
guidelines of the National Comprehensive Cancer Network
(http://www.nccn.com/ﬁles/cancer-guidelines/breast/index.
html#/1, last accessed February 1, 2013) indicated the
importance of biopsy to conﬁrm recurrence, if possible, and its
necessity if either HER2 or hormone receptor testing was
negative or never performed. The extent to which these
guidelines are practiced is unknown. Issues include reim-
bursement, the pain and morbidity for the patient, and tech-
nical difﬁculties (especially for the biopsy of bonemetastases).
Botteri et al91 reported that biopsies of liver metastasis
were useful for conﬁrmation or exclusion of advanced
disease and for reassessment of the biology of the metastatic
disease, and thus can contribute to deﬁning a more effective
treatment strategy, either by proposing new treatment
options or avoiding ineffective therapies. Indeed, they
observed a positive effect of liver biopsy on survival in
patients with early metastases. Clearly, additional larger
studies will be needed to validate the technique.
Can CTCs Guide Personalized Therapy?
A minimally invasive tumor assessment would be preferable
to an invasive biopsy. Serial reconﬁrmation of disease
biocharacteristics before commencing new therapy and at
relapse could potentially personalize and optimize thera-
peutic decisions. Detection and biocharacterization of1090circulating tumor cells (CTCs) in the peripheral blood of
patients with advanced breast cancer could optimally serve
as a real-time tumor biopsy.92 The cardinal feature not only
of breast cancer metastases but of all cancer metastases is
the circulation of cancer cells from a primary tumor to
distant organs such as lung, liver, bone, or brain.
CTCs are rare events, occurring at rates as low as one cell
per 105 to 107 peripheral blood mononucleated cells. Their
detection is complicated by signiﬁcant leukocyte contami-
nation.92 Recent advanced methodologies in the detection
and characterization of CTCs include microchips, ﬁltration,
microscopic approaches, highly sensitive quantitative
RT-PCR, the FDA-approved CellSearch system (Janssen
Diagnostics, Raritan, NJ) system, or a combination of
molecular and imaging methods.93 Detection based on
EpCAM or cytokeratin expression on CTCs is potentially
complicated by the epithelialemesenchymal transition,
where expression of these proteins is lost.94
Prospective studies have demonstrated that detection of
CTCs in metastatic breast cancer can successfully predict
progression-free survival and overall survival.95 The
German SUCCESS trial is the largest study (performed with
the CellSearch system) to evaluate the prognostic relevance
of CTCs in breast cancer patients in the adjuvant setting.96
In 2007, CTCs were cited for the ﬁrst time in the Amer-
ican Society of Clinical Oncology recommendations on
tumor markers.97
Although CTCs are promising, several issues in the liter-
ature need resolution before CTCs can be proposed as a part of
a personalized medicine regimen. The proportion of CTCs
that are metastatically competent (as opposed to shed tumor
cells destined to die) is unclear. According to the experimental
literature, the vast majority of tumor cells shed into the
circulation never form a metastatic lesion.72 Can therapeutic
decisions bemade on the characteristics of all CTCs obtained,
or do we need to know which ones are metastatically
competent? In addition, it is known that the molecular char-
acteristics of CTCs do not always match those of the primary
tumor and that in the same blood sample, heterogeneous CTC
subpopulations with different hormone receptor and other
phenotypes coexist.98,99 Given our increasing ability to
proﬁle CTCs not only for standard histopathological markers
but also for gene expression, mutations, and epigenetic
alterations, the prognostic and predictive ability of these
subpopulations of tumor cellsmust be conﬁrmed. Thismay be
best accomplished by the collection of longitudinal banks of
CTCs with associated patient follow-up data to semi-
personalized therapy, for use inmultiple molecular platforms.
Finally, we note that CTCs are not obtained in all patients,
even some with metastatic disease; necessarily, CTCs can
provide information only when they are available.
miRNAs
Other components of blood, such as standard cancer markers
and microRNAs (miRNAs) may also have predictive ability.ajp.amjpathol.org - The American Journal of Pathology
Challenges in Breast Cancer MetastasismiRNAs, which are small noncoding RNA molecules con-
sisting of approximately 22 nucleotides, have been identiﬁed
in the serum of cancer patients.100 miRNAs are thought to
regulate the expression of multiple genes, based on their
binding sites, and are involved in different cellular
processes, including apoptosis, differentiation, metabolism,
and cancer.101 It will be of interest to determine whether
a speciﬁc set of miRNAs control metastasis and/or therapy
resistance pathways.
New Trial Designs Will Be Needed
Towhat extent is our failure to improve the lives of metastatic
breast cancer patients, or those at high risk of developing
metastases, a failure not of drug development, but of clinical
trial design?
Even before personalized medicine is developed, new
trial designs will be needed to address the goal of metastasis
prevention, both in the adjuvant setting and for prevention
of additional metastases in the limited metastatic setting
(secondary prevention). The preclinical literature abounds
with evidence that compounds currently in clinical trials
prevent the formation of metastases (they are given early
and continuously, and fewer metastases develop at the
endpoint).102,103 We have advocated for phase II random-
ized primary and secondary metastasis prevention trials.104
In brief, for semipersonalized groups, patients could
receive standard of care and be randomized to a metastasis
preventive agent or placebo. The endpoint of interest would
be time to the development of a ﬁrst metastasis, or time to
the development of a new metastasis. This type of trial
design could validate drugs with efﬁcacy to hold single
tumor cells or micrometastases in check, but that cannot
shrink an established lesion in standard phase II metastatic
setting trials. It is noteworthy that the primary prevention
scheme dovetails with recent FDA guidance on neoadjuvant
clinical trial designs.105 Thus, patients who do not achieve
a complete pathological response could be optimal candi-
dates for primary metastasis prevention trials.
New trials will also be needed to address the induction
and breakdown of metastatic dormancy as this phenotype is
drugged.106 Long-term therapy may induce drug insensi-
tivity (resistance) as well as prolonged toxicity.
Trials with other designs that may be particularly germane
to the personalization of treatment are underway. In the
SAFIR-01 trial, coordinated by Dr. Fabrice André, high-
throughput technologies (microarray gene expression
proﬁling and comparative genomic hybridization array,
OncoMap platform, and next-generation sequencing) are
used to identify metastatic breast cancer patients whose
tumor metastases present speciﬁc molecular alterations to
add a targeted regimen to the standard treatment. More than
400 mutations are analyzed. Moreover, these technologies
determine whether such genomic alterations are single (ex-
pected efﬁcacy of a single agent) or multiple (rationale for
a combination). This approach attempts to improveThe American Journal of Pathology - ajp.amjpathol.orgpersonalized medicine and to lower risk, compared with
a single-biomarker trial. However, the high cost of the high-
throughput technologies and the small size that a personal-
ized approach can reach must be considered as limitations.107
The role of adaptive trial designs is being developed in
the I-SPY trial series, although in the neoadjuvant setting.
Coordinated by Drs. Laura Esserman and Donald Berry, the
I-SPY 2 trial uses biomarkers (HR status, HER2 status, and
the MammaPrint 70-gene signature status) to stratify
patients based on their predicted potential response to
treatment, and evaluates phase II drugs in combination with
standard chemotherapy.108 An adaptive trial can use more
than one type of adaptation, such as stopping a treatment
early, changing or dropping arms or doses, and changing the
proportion of patients randomized to each arm. This
approach allows a rapid identiﬁcation of effective new
agents and drug combinations, as well as of the breast
cancer subtypes that will beneﬁt from the new therapy. It is
hoped that this trial design will also reduce adverse effects
and spare patients from enrolling in trials from which they
will not beneﬁt. How adaptive designs ﬁt into the adjuvant
and metastatic settings remains incompletely resolved.
Redundancy
The metastatic process is inherently redundant, in that
multiple pathways can accomplish the same task. For
example, tumor cell motility may be mediated by integrin,
Rac1, Rho, MMP, FAK, multiple growth factors, and other
signaling pathways.1 Although each of these pathways is
mechanistically validated, an inhibitor to one pathway likely
selects for the rare tumor cell that can use an alternative
pathway for the same function. The same genomic insta-
bility that fuels this adaptive response to the mechanistic
requirements of metastasis likely also promotes an adaptive
response for the development of resistance to chemother-
apies and hormonal therapies. Personalized medicine may
actually be most effective when administered as a cocktail
of therapies to combat both the complex molecular wiring
and the predicted resistance mechanisms, similar to the
cocktails effective for the treatment of AIDS.
Patient Advocate Perspective
The life expectancy formost individualswithmetastatic breast
cancer is still less than 5 years. Although patients receive
semipersonalized treatment, the life-saving efﬁcacy observed
in the adjuvant setting is absent from the metastatic setting.
Treatment of metastatic breast cancer is largely a hit-or-miss
proposition characterized by increasing resistance with
successive lines of therapy. Although some guidelines are
available, they are basedbynecessity on consensus ofwhat has
been shown to be best for groups of patients in clinical trials.
Apart from the predictive value of HER2 and ER status in
governing treatment choices, treatment of metastatic disease
is almost wholly an empirical process, especially in the later1091
Marino et alstages of the disease, involving a series of trial-and-error
attempts to control the cancer. The lack of speciﬁc predic-
tive biomarkers for treatment response means that weeks to
months of toxic and expensive treatments are undergone
before scans indicate whether a treatment is working.
We still understand little about why one treatment works
and another does not. A much more personalized approach
would include other factors than the ER and HER2
expression of a tumor. Because treatment efﬁcacy and both
de novo and acquired resistance may be affected by other
than genomic factors, perhaps we need to use the term
personalized medicine more inclusively.
Many relevant and urgent questions need answering.
What drives the dormant cancer cells to grow again or send
outgrowths from quiescent, stable lesions? Is it an individ-
ual’s metabolism? Is it the microenvironment and stroma
surrounding the cells? Why do some patients get only bone
metastases? Or only one lesion in one organ? It seems as if
sequencing the genome of one individual lesion may not
answer such questions.
If a more truly personalized approach comes within
ﬁnancial and logistic reach, the hope is that it could greatly
boost not only the quantity but also the quality of lives. The
dream of living a relatively normal life span could become
a reality. The challenges, however, seem too steep, and for
many reasons. How will researchers, each with tiny pieces
of a giant puzzle, come together to make sense of the
increasing amounts of data? Who is going to develop drugs
that may have quite a limited market? Who will the payers
be? Who will beneﬁt from the personalized genomic
approach? Finally, how will personalized medicine, and
treatment of metastatic breast cancer in particular, reach
those living in low-resource countries?References
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